Our Approach

Our strong and efficient R&D approach requires we have a deep understanding of the disease, genetics, molecular profile and biomarker profile to find biotechnologies that match the disease profile. We are focusing disease by disease, patient segment by patient segment to improve outcomes.

Lead Product Candidate

Bertilimumab, supported by 1,500 peer-reviewed studies, targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations. Learn more about Bertilimumab.

Our Pipeline

We have a rich pipeline of multiple medications supported by consistent science. We focus on high risk disruptive innovation with potential earlier partnership and higher value inflection points. See our pipeline.

U.S. Office

430 East 29th Street
Suite 940
New York, NY 10016
Tel: (646) 440-9310
eFax: (917) 398-1915

Israel Office

4th Floor, Minrav Building
Kiryat Hadassah 1

Ein Kerem, Jerusalem, 91120

Tel: +972 988866612